193 related articles for article (PubMed ID: 14699176)
1. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison.
Agress H; Cooper BZ
Radiology; 2004 Feb; 230(2):417-22. PubMed ID: 14699176
[TBL] [Abstract][Full Text] [Related]
2. The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography.
Ozkol V; Alper E; Aydin N; Ozkol HF; Topal NB; Akpinar AT
Nucl Med Commun; 2010 Feb; 31(2):128-36. PubMed ID: 19858768
[TBL] [Abstract][Full Text] [Related]
3. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance.
Israel O; Yefremov N; Bar-Shalom R; Kagana O; Frenkel A; Keidar Z; Fischer D
J Nucl Med; 2005 May; 46(5):758-62. PubMed ID: 15872347
[TBL] [Abstract][Full Text] [Related]
4. Detection of unexpected additional primary malignancies with PET/CT.
Ishimori T; Patel PV; Wahl RL
J Nucl Med; 2005 May; 46(5):752-7. PubMed ID: 15872346
[TBL] [Abstract][Full Text] [Related]
5. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.
Choi JY; Lee KS; Kwon OJ; Shim YM; Baek CH; Park K; Lee KH; Kim BT
J Clin Oncol; 2005 Oct; 23(30):7654-9. PubMed ID: 16234527
[TBL] [Abstract][Full Text] [Related]
6. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results.
Kamel EM; Thumshirn M; Truninger K; Schiesser M; Fried M; Padberg B; Schneiter D; Stoeckli SJ; von Schulthess GK; Stumpe KD
J Nucl Med; 2004 Nov; 45(11):1804-10. PubMed ID: 15534047
[TBL] [Abstract][Full Text] [Related]
7. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG.
Nakamoto Y; Osman M; Wahl RL
Clin Nucl Med; 2003 Apr; 28(4):302-7. PubMed ID: 12642709
[TBL] [Abstract][Full Text] [Related]
9. [Unexpected focal bowel 18-FDG uptake sites: should they be systematically investigated?].
Tessonnier L; Gonfrier S; Carrier P; Valerio L; Mouroux J; Benisvy D; Viau P; Girma A; Bussière F; Darcourt J
Bull Cancer; 2008 Nov; 95(11):1083-7. PubMed ID: 19036681
[TBL] [Abstract][Full Text] [Related]
10. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
[TBL] [Abstract][Full Text] [Related]
11. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results.
Kei PL; Vikram R; Yeung HW; Stroehlein JR; Macapinlac HA
AJR Am J Roentgenol; 2010 May; 194(5):W401-6. PubMed ID: 20410385
[TBL] [Abstract][Full Text] [Related]
12. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
13. Whole-body [18F]FDG PET in the management of metastatic brain tumours.
Kim DG; Kim CY; Paek SH; Lee DS; Chung JK; Jung HW; Cho BK
Acta Neurochir (Wien); 1998; 140(7):665-73; discussion 673-4. PubMed ID: 9781280
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings.
Drenth JP; Nagengast FM; Oyen WJ
Eur J Nucl Med; 2001 Dec; 28(12):1766-9. PubMed ID: 11734913
[TBL] [Abstract][Full Text] [Related]
15. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
16. Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma?
Tan JC; Chatterton BE
Hell J Nucl Med; 2012; 15(3):202-5. PubMed ID: 23106051
[TBL] [Abstract][Full Text] [Related]
17. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
[TBL] [Abstract][Full Text] [Related]
19. Incidental PET/CT findings in the cancer patient: how should they be managed?
Beatty JS; Williams HT; Aldridge BA; Hughes MP; Vasudeva VS; Gucwa AL; David GS; Lind DS; Kruse EJ; McLoughlin JM
Surgery; 2009 Aug; 146(2):274-81. PubMed ID: 19628085
[TBL] [Abstract][Full Text] [Related]
20. Combined functional and structural evaluation of cancer patients with a hybrid camera-based PET/CT system using (18)F-FDG.
Israel O; Mor M; Gaitini D; Keidar Z; Guralnik L; Engel A; Frenkel A; Bar-Shalom R; Kuten A
J Nucl Med; 2002 Sep; 43(9):1129-36. PubMed ID: 12215549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]